The Cellares Cell Shuttle platform was the first to receive the FDA’s Advanced Manufacturing Technology (AMT) designation, which offers partners additional touchpoints and priority review mechanisms ...
Autolus Therapeutics plc , a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the first Integrated ...
Age-adjusted D-dimer cutoffs can safely rule out deep vein thrombosis (DVT) in many suspected cases, according to the ...
MedPage Today on MSN
DVT Assessment Strategy Safely Expands Rule-Out
A prospective validation study found that age-adjusted D-dimer thresholds can safely rule out lower extremity DVT for more ...
Researchers have developed a new computational approach that uncovers possible drugs for specific cellular targets for ...
A single dose of intravenous (IV) iron dextran is the most cost-effective treatment for women with heavy menstrual bleeding ...
Adults with type 2 diabetes and cancer who used a GLP-1 had a lower risk for death and hospitalization compared with adults ...
Peter Voorhees, MD, emphasizes the importance of carefully determined early regimens for smoldering myeloma and involving ...
An oncology pharmacist shares how a treatment takes a different approach to treating chronic graft-versus-host disease (GVHD) ...
Autolus will evaluate Cellares' fully automated, high-throughput manufacturing platform in preparation for expansion into new indications Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage ...
Coronary artery disease characterized by vascular calcification poses significant challenges in the field of interventional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback